Ono Pharmaceutical Co., Ltd.
Native name
Company typePublic (K.K)
TYO: 4528
Founded1717; 307 years ago (1717) as Fushimiya Ichibei apothecary
FounderIchibei Ono I
Chuo-ku, Osaka, 541-8564
Area served
Key people
Gyo Sagara
(President and CEO)
RevenueIncrease USD 6.3 billion (FY 2023)
USD 848.1 million (FY 2023)
Number of employees
3,687 (2023)
WebsiteOfficial website
Footnotes / references
Ono Pharmaceutical's headquarters in Chūō-ku, Osaka, Japan

Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka.,[4] and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.[5]

Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: 小野市兵衛) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: 小野薬品工業株式会社) in 1948.[6]

Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.[7]

Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.[8]

In 2024, Harvard University and Ono Pharmaceutical (ONO) entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work.[9]

See also


  1. ^ "Company Profile". Ono Pharmaceutical. Retrieved January 30, 2019.
  2. ^ "Company Profile". Nikkei Asian Review. Nikkei Inc. Retrieved January 30, 2019.
  3. ^ "About the company". Financial Times. Retrieved January 30, 2019.
  4. ^ Ono Pharmaceutical - Manufacturing
  5. ^ Ono Pharmaceutical - Research & Development
  6. ^ P. Reed Maurer (January 25, 2013). They Do Well Who Do Good: Insights into Japan's Pharmaceutical Industry. Trafford. p. 132. ISBN 978-1-4669-5347-5.
  7. ^ "Company Overview of Ono Pharmaceutical Co., Ltd". bloomberg.com. Retrieved October 4, 2018.
  8. ^ "Spotlight on New Cancer Immunotherapy: Ono Pharmaceutical's Opdivo". Nippon.com. February 9, 2016. Retrieved October 4, 2018.
  9. ^ "Harvard partners with Ono Pharma to accelerate development of novel therapeutics". TechTransferCentral. March 18, 2024.